Report results for the K031 COVID-19 study
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 14 Jan 2021
- Due
- 31 Mar 2021
- Delivered
- Q1 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“2020 COVID-19 (K031) study – Q1’2021”
What we found
Evidence strength A What the grades mean
The company reported positive results from the K031 clinical study of KB109 in patients with mild-to-moderate COVID-19, referencing interim findings that were released earlier in 2021.
-
A Kaleido Biosciences, Inc. 8-K filed 2021-05-04
“Consistent with the interim findings we reported earlier this year, results from the full dataset demonstrated that KB109 has a favorable safety and tolerability profile” ✓ confirmed on the page
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- K031 study results
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Late”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and reads it as “no_evidence”.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Kaleido Biosciences, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C751299-022080 · Corrections policy